{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T21:37:23Z","timestamp":1761860243968,"version":"build-2065373602"},"reference-count":32,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","nursingoutlook.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nursing Outlook"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.outlook.2023.102004","type":"journal-article","created":{"date-parts":[[2023,7,8]],"date-time":"2023-07-08T17:39:34Z","timestamp":1688837974000},"page":"102004","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Enhancing engagement between legislators and nursing to increase buprenorphine access"],"prefix":"10.1016","volume":"71","author":[{"given":"Deborah S.","family":"Finnell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5785-7473","authenticated-orcid":false,"given":"JoEllen","family":"Schimmels","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4531-9317","authenticated-orcid":false,"given":"Matthew","family":"Tierney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"year":"2022","series-title":"Psychiatric-mental health nursing: Scope and standards of practice","key":"10.1016\/j.outlook.2023.102004_bib1"},{"year":"2022","series-title":"Addictions nursing: Scope and standards of practice","key":"10.1016\/j.outlook.2023.102004_bib2"},{"issue":"1","key":"10.1016\/j.outlook.2023.102004_bib3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13722-022-00321-6","article-title":"Perceptions of buprenorphine barriers and efficacy among nurse practitioners and physician assistants","volume":"17","author":"Andraka-Christou","year":"2022","journal-title":"Addiction Science & Clinical Practice"},{"issue":"2","key":"10.1016\/j.outlook.2023.102004_bib4","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/jrh.12404","article-title":"Prescribing practices of nurse practitioners and physician assistants waivered to prescribe buprenorphine and the barriers they experience prescribing buprenorphine","volume":"36","author":"Andrilla","year":"2020","journal-title":"The Journal of Rural Health"},{"issue":"1","key":"10.1016\/j.outlook.2023.102004_bib5","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1111\/jrh.12569","article-title":"Tracking the geographic distribution and growth of clinicians with a DEA waiver to prescribe buprenorphine to treat opioid use disorder","volume":"38","author":"Andrilla","year":"2022","journal-title":"The Journal of Rural Health"},{"key":"10.1016\/j.outlook.2023.102004_bib6","unstructured":"Centers for Disease Control and Prevention. (2022a). Death rate maps & graphs. https:\/\/www.cdc.gov\/drugoverdose\/deaths\/index.html."},{"key":"10.1016\/j.outlook.2023.102004_bib7","unstructured":"Centers for Disease Control and Prevention. (2022b). Waves of the opioid epidemic.\u00a0https:\/\/www.cdc.gov\/opioids\/basics\/epidemic.html."},{"key":"10.1016\/j.outlook.2023.102004_bib8","unstructured":"Centers for Disease Control and Prevention. (2022c). Drug overdose mortality by state.\u00a0https:\/\/www.cdc.gov\/nchs\/pressroom\/sosmap\/drug_poisoning_mortality\/drug_poisoning.htm."},{"key":"10.1016\/j.outlook.2023.102004_bib9","unstructured":"Centers for Disease Control and Prevention.\u00a0(2023). Understanding drug overdoses and deaths.\u00a0https:\/\/www.cdc.gov\/drugoverdose\/epidemic\/index.html."},{"issue":"5","key":"10.1016\/j.outlook.2023.102004_bib10","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2023.1080","article-title":"Cost-effectiveness of increasing buprenorphine treatment initiation, duration, and capacity among individuals who use opioids","volume":"4","author":"Claypool","year":"2023","journal-title":"JAMA Health Forum"},{"key":"10.1016\/j.outlook.2023.102004_bib11","unstructured":"Comprehensive Addiction and Recovery Act of 2016.\u00a0(2016). P.L. 114-198. Retrieved from\u00a0https:\/\/www.congress.gov\/114\/plaws\/publ198\/PLAW-114publ198.pdf."},{"key":"10.1016\/j.outlook.2023.102004_bib12","unstructured":"Consolidated Appropriations Act of\u00a02023. (2023). P.L. 117-328. Retrieved from\u00a0https:\/\/www.policymed.com\/wp-content\/uploads\/2023\/01\/CME-DEA-Omnibus-Bill-2023-Clean-Version-Requiring-Prescribers-of-Controlled-Substances-to-Complete-Training.pdf."},{"issue":"5","key":"10.1016\/j.outlook.2023.102004_bib13","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.outlook.2021.03.012","article-title":"Expanding access to nurse-managed medication for opioid use disorder","volume":"69","author":"Cos","year":"2021","journal-title":"Nursing Outlook"},{"issue":"2","key":"10.1016\/j.outlook.2023.102004_bib14","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.annemergmed.2021.03.023","article-title":"Improve access to care for opioid use disorder: a call to eliminate the X-waiver requirement now","volume":"78","author":"D\u2019Onofrio","year":"2021","journal-title":"Annals of Emergency Medicine"},{"key":"10.1016\/j.outlook.2023.102004_bib15","unstructured":"Drug Addiction Treatment Act of 2000.\u00a0(2000).\u00a021 USC 801\u00a73501-3502."},{"issue":"3","key":"10.1016\/j.outlook.2023.102004_bib16","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1001\/jamapsychiatry.2018.3685","article-title":"Buprenorphine deregulation and mainstreaming treatment for opioid use disorder: X the X waiver","volume":"76","author":"Fiscella","year":"2019","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"10.1016\/j.outlook.2023.102004_bib17","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0376-8716(03)00055-3","article-title":"From morphine clinics to buprenorphine: regulating opioid agonist treatment of addiction in the United States","volume":"70","author":"Jaffe","year":"2003","journal-title":"Drug and Alcohol Dependence"},{"issue":"3","key":"10.1016\/j.outlook.2023.102004_bib18","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/jnu.12871","article-title":"Eliminate the buprenorphine DEA X waiver: Justification using a policy analysis approach","volume":"55","author":"Jones","year":"2023","journal-title":"Journal of Nursing Scholarship"},{"issue":"29","key":"10.1016\/j.outlook.2023.102004_bib19","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/adaw.32440","article-title":"ASAM supports eliminating the x-waiver for buprenorphine","volume":"31","author":"Knopf","year":"2019","journal-title":"Alcoholism & Drug Abuse Weekly"},{"key":"10.1016\/j.outlook.2023.102004_bib20","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s13181-019-00728-9","article-title":"ACMT position statement: remove the waiver requirement for prescribing buprenorphine for opioid use disorder","volume":"15","author":"Marino","year":"2019","journal-title":"Journal of Medical Toxicology"},{"key":"10.1016\/j.outlook.2023.102004_bib21","doi-asserted-by":"crossref","DOI":"10.1177\/20552076211048985","article-title":"Get waivered remote: Nationwide, remote DEA-x waiver course in response to COVID-19","volume":"7","author":"Martin","year":"2021","journal-title":"Digital Health"},{"issue":"2","key":"10.1016\/j.outlook.2023.102004_bib22","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1177\/10775587211004311","article-title":"The association between scope of practice regulations and nurse practitioner prescribing of buprenorphine after the 2016 opioid bill","volume":"79","author":"Nguyen","year":"2022","journal-title":"Medical Care Research and Review"},{"key":"10.1016\/j.outlook.2023.102004_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2020.108083","article-title":"Buprenorphine prescription dispensing rates and characteristics following federal changes in prescribing policy, 2017-2018: A cross-sectional study","volume":"213","author":"Roehler","year":"2020","journal-title":"Drug and Alcohol Dependence"},{"issue":"6","key":"10.1016\/j.outlook.2023.102004_bib24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40263-019-00637-z","article-title":"Buprenorphine treatment for opioid use disorder: An overview","volume":"33","author":"Shulman","year":"2019","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.outlook.2023.102004_bib25","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1377\/hlthaff.2022.00310","article-title":"Buprenorphine treatment: Advanced Practice Nurses add capacity: Study examines office-based buprenorphine treatment capacity for opioid use disorder","volume":"41","author":"Spetz","year":"2022","journal-title":"Health Affairs"},{"issue":"14","key":"10.1016\/j.outlook.2023.102004_bib26","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1001\/jama.2019.0834","article-title":"Nurse practitioner and physician assistant waivers to prescribe buprenorphine and state scope of practice restrictions","volume":"321","author":"Spetz","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.outlook.2023.102004_bib27","unstructured":"Substance Abuse and Mental Health Services Administration. (2023a). Removal of DATA waiver (X-waiver) requirement. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/removal-data-waiver-requirement."},{"key":"10.1016\/j.outlook.2023.102004_bib28","unstructured":"Substance Abuse and Mental Health Services Administration. (2023b). Recommendations for curricular elements in substance use disorders training. https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/provider-support-services\/recommendations-curricular-elements-substance-use-disorders-training."},{"key":"10.1016\/j.outlook.2023.102004_bib29","unstructured":"Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act or the SUPPORT for Patients and Communities Act.\u00a0(2018). P.L. 115-271.\u00a0https:\/\/www.congress.gov\/bill\/115th-congress\/house-bill\/6."},{"issue":"4","key":"10.1016\/j.outlook.2023.102004_bib30","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1080\/08897077.2015.1101733","article-title":"Advanced practice nurses: Increasing access to opioid treatment by expanding the pool of qualified buprenorphine prescribers","volume":"36","author":"Tierney","year":"2015","journal-title":"Substance Abuse"},{"key":"10.1016\/j.outlook.2023.102004_bib31","unstructured":"U.S. Department of Health and Human Services.\u00a0(2022, December). Early changes in waivered clinicians and utilization of buprenorphine for opioid use disorder after implementation of the 2021 HHS Buprenorphine Practice Guidelines. Office of the Assistant Secretary for Planning and Evaluation. https:\/\/aspe.hhs.gov\/sites\/default\/files\/documents\/facbce1704035fded1034192d148304d\/buprenorphine-practice-guideline-early-impacts.pdf."},{"key":"10.1016\/j.outlook.2023.102004_bib32","unstructured":"Varghese,\u00a0R.,\u00a0Johnson,\u00a0R.,\u00a0Feng,\u00a0B.,\u00a0Liu,\u00a0M.,\u00a0Sanford,\u00a0A.,\u00a0Dowell,\u00a0P.,\u00a0Desai,\u00a0K.,\u00a0Harris,\u00a0H., &\u00a0Rajakannan,\u00a0T.\u00a0(2019).\u00a0Final Research Report: Buprenorphine Prescribing by Nurse Practitioners, Physician Assistants, and Physicians after CARA 2016. IMPAQ International, LLC. https:\/\/www.macpac.gov\/publication\/buprenorphine-prescribing-by-nurse-practitioners-physician-assistants-and-physicians-after-cara-2016\/."}],"container-title":["Nursing Outlook"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0029655423001094?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0029655423001094?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T09:57:00Z","timestamp":1758448620000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0029655423001094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S0029655423001094"],"URL":"https:\/\/doi.org\/10.1016\/j.outlook.2023.102004","relation":{},"ISSN":["0029-6554"],"issn-type":[{"type":"print","value":"0029-6554"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enhancing engagement between legislators and nursing to increase buprenorphine access","name":"articletitle","label":"Article Title"},{"value":"Nursing Outlook","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.outlook.2023.102004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"102004"}}